SUPPORT for Patients and Communities Reauthorization Act of 2025

What happened: The SUPPORT for Patients and Communities Reauthorization Act of 2025 was signed into law (Public Law 119-44), reauthorizing HHS grant programs for substance use disorder treatment, overdose prevention, and mental health services through FY2030. This is a completed legislative action — the bill passed through the 119th Congress and was enacted on or shortly after May 29, 2025. The money trail: This bill is an authorization — it sets spending ceilings for the reauthorized grant programs but does not appropriate actual funds. Actual fiscal year allocations depend on subsequent appropriations bills. The CRS summary indicates reauthorization for multiple grant programs including those for pregnant/postpartum women, youth prevention, housing for recovery, community recovery organizations, and loan repayment for SUD healthcare providers. No single total dollar amount is specified in the bill text provided, but the structural effect is predictable. Structural winners: Diagnostic companies LH and DGX benefit from sustained federal funding for SUD and mental health programs that drive lab test volume for toxicology and medication monitoring. Pharmaceutical distributor CAH benefits from distribution of naloxone and other SUD medications funded through grants. The April 2026 Executive Order on Accelerating Medical Treatments for Serious Mental Illness directly amplifies this bill's impact on psychedelic therapy developers CMPS and MNMD by reducing regulatory barriers and creating a pathway toward federal reimbursement. Recent market data diagnostics: Despite the long-term tailwind from this legislation, LH and DGX have both declined over the past 7 days (-4.79% and -4.39% respectively) and 30 days (-1.75% and -0.24%). LH closed at $259.57 on April 28, 2026, down from $272.62 on April 22. DGX closed at $195.05, down from $204 on April 22. This near-term weakness likely reflects broader healthcare sector headwinds — HCA dropped 8.36% and UHS dropped 10.06% in the same 7-day period. CAH bucked the trend with a +2.52% 7-day gain, closing at $205.61. Timeline: No remaining legislative steps — the bill is signed law. The actionable period is the FY2026-FY2030 authorization horizon. Investors should monitor the FY2026 and FY2027 appropriations bills to see actual funding levels for the reauthorized programs.